Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?

Immune checkpoint inhibitors (ICIs) are drugs growingly employed in cancer immunotherapy which have significantly improved the prognosis of several tumours. ICIs act by restoring the “exhausted” immune system and increasing the number of T cells active against pathogens losing tolerogenic signalling...

Full description

Saved in:

Bibliographic Details
Published in:	BMC infectious diseases Vol. 23; no. 1; pp. 1 - 5
Main Authors:	Azzarà, Cecilia, Lombardi, Andrea, Gramegna, Andrea, Ori, Margherita, Gori, Andrea, Blasi, Francesco, Bandera, Alessandra
Format:	Journal Article
Language:	English
Published:	London BioMed Central 04.09.2023 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Adenocarcinoma Amikacin Antibiotics Asthenia Azithromycin Bronchus Cancer immunotherapy Cancer therapies Care and treatment Case Report Case reports Clinical medicine Demographic aspects Development and progression Diagnosis Drug therapy Ethambutol Health aspects Health services Immune checkpoint inhibitors Immune response Immune system Immune-related adverse events Immunity (Disease) Immunosuppressive agents Immunotherapy Infections Infectious Diseases Inhibitors Internal Medicine Lavage Lung cancer Lung diseases Lymphocytes Lymphocytes T Medical imaging Medical Microbiology Medicine Medicine & Public Health Monoclonal antibodies Mycobacterial infections Mycobacterium chimaera Non-tuberculous mycobacteria NTM-LD Parasitology Patients PD-L1 protein Pemetrexed Prognosis Receiving Respiratory tract Rifampin Risk factors Signs and symptoms Sputum Superinfection T cells Tropical Medicine Tuberculosis Weight loss Italy United States > US Non-tuberculous mycobacteria Immune checkpoint inhibitors Immune-related adverse events NTM-LD
ISSN:	1471-2334, 1471-2334
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!